[Federal Register: March 14, 2001 (Volume 66, Number 50)]
[Notices]
[Page 14910-14911]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr14mr01-61]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, Public Health Service, DHHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by agencies of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of federally-funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for companies and may also be available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by writing to the indicated
licensing contact at the Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A
signed Confidential Disclosure Agreement will be required to receive
copies of the patent applications.
Novel Attenuated Strains of Mycobacterium Tuberculosis
CE Barry, Y Yuan, D Crane (NIAID)
DHHS Reference No. E-238-97/2 filed Jun 27, 2000
Licensing Contact: Carol Salata; 301/496-7735 ext. 232; e-mail:
salatac@od.nih.gov
This invention provides for novel attenuated strains of
Mycobacterium tuberculosis and M. bovis. Attenuation is achieved by
deleting the gene encoding the alpha-crystallin heat shock protein
(``acr gene''). This gene contributes to the virulence of the organism.
Since this strain is isogenic with virulent M. tuberculosis but for
this deletion, the full complement of antigens remains present and the
organism is viable in vitro. The invention provides for vaccines and
methods of vaccinating mammals for protection against Mycobacterium sp.
that cause tuberculosis. This invention was filed as PCT/US98/14227 on
Jul 09, 1998.
Methods and Compositions for Transforming Dendritic Cells and
Activating T Cells
Patrick Hwu, Mark E. Reeves, Steven A. Rosenberg (NCI)
DHHS Reference Nos. E-040-96/0 filed Feb. 08, 1996, E-040-96/1 filed
Feb. 07, 1997
(PCT/US97/02063); E-040-96/2 filed Jan. 07, 1999
Licensing Contact: Elaine White; 301/496-7056 ext. 282; e-mail:
gesee@od.nih.gov
This invention describes a novel method for making transformed
dendritic cells, which are potent antigen presenting cells capable of
stimulating the immune system. Hematopoietic stem cells are transformed
with a specific nucleic acid; the transformed cell is then
differentiated into a dendritic cell in vitro. The nucleic acid
produces a polypeptide, fragments of which are expressed on the major
histocompatibility complex (MHC) receptors on the surface of the
dendritic cell. These cells may then be used to activate T cells
against specific target antigens. Use of specific antigens for
transduction into the dendritic cells is described. The invention
therefore may represent a valuable tool for use in the treatment of a
number of diseases,
[[Page 14911]]
including various cancers and viral infections such as HIV.
Dated: March 6, 2001.
Jack Spiegel,
Director, Division of Technology, Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. 01-6273 Filed 3-13-01; 8:45 am]
BILLING CODE 4140-01-P